Pneumococcal Conjugate Vaccine Recommendations
All adults aged ≥50 years should receive a single dose of pneumococcal conjugate vaccine (PCV21, PCV20, or PCV15), with specific recommendations varying based on age, underlying medical conditions, and prior vaccination history. 1
Primary Indications for PCV
Age-Based Recommendations
- Adults ≥50 years: Universal recommendation for all PCV-naïve adults 1
- Adults ≥65 years: All adults in this age group should receive PCV regardless of health status 2
Risk-Based Recommendations (Ages 19-64 years)
High-Risk Conditions (requiring PCV):
- Immunocompromising conditions (chronic renal failure, nephrotic syndrome, immunodeficiency, iatrogenic immunosuppression, generalized malignancy, HIV infection, Hodgkin disease, leukemia, lymphoma, multiple myeloma, solid organ transplant)
- Congenital or acquired asplenia
- Sickle cell disease or other hemoglobinopathies
- CSF leak
- Cochlear implant 2
Chronic Medical Conditions (requiring PCV):
- Alcoholism
- Chronic heart disease (including congestive heart failure and cardiomyopathies)
- Chronic liver disease
- Chronic lung disease (including COPD, emphysema, and asthma)
- Cigarette smoking
- Diabetes mellitus 2
Vaccine Selection and Timing
For Previously Unvaccinated Adults
Adults ≥65 years or high-risk adults 19-64 years:
- Option 1: Single dose of PCV21 or PCV20 (series complete)
- Option 2: PCV15 followed by PPSV23 ≥1 year later (≥8 weeks for immunocompromised, CSF leak, or cochlear implant) 2
For Previously Vaccinated Adults
If received PPSV23 only:
- Give PCV21, PCV20, or PCV15 ≥1 year after last PPSV23 dose 2
If received PCV13 only:
- Adults ≥65 years: Give PCV21, PCV20, or PPSV23 ≥1 year after PCV13 2
- Adults 19-64 years with high-risk conditions: Give PCV21 or PCV20 ≥1 year after PCV13, or PPSV23 ≥8 weeks after PCV13 2
If received both PCV13 and PPSV23 at age ≥65:
- Shared clinical decision-making for additional PCV21 or PCV20 ≥5 years after last dose 2
Important Clinical Considerations
Geographic Serotype Considerations
In communities with high proportions (≥30%) of serotype 4 pneumococcal disease (particularly in the western United States), PCV20 may be preferred over PCV21 since PCV21 does not contain serotype 4 2. This is a critical pitfall to avoid—always consider local epidemiology when selecting between vaccines.
Coadministration
PCVs can be administered simultaneously with other age-appropriate vaccines at the same visit, provided no specific contraindications exist 2
Contraindications
- Severe allergic reaction (anaphylaxis) to any vaccine component
- For PCVs specifically: severe allergic reaction to any diphtheria toxoid-containing vaccine 2
Key Timing Intervals Summary
- PCV to PPSV23: ≥1 year (standard); ≥8 weeks (immunocompromised/CSF leak/cochlear implant)
- PPSV23 to PCV: ≥1 year
- PCV13 to newer PCV (PCV20/21): ≥1 year (standard); ≥5 years if prior PPSV23 also given
- Between PPSV23 doses: ≥5 years 2
The 2024 ACIP guidelines represent a significant expansion from previous recommendations, now including all adults ≥50 years rather than just ≥65 years, reflecting the substantial disease burden in younger adults with and without risk factors 1.